Semax
Semax (ACTH 4-7 Proline-Glycine-Proline)
Russia's premier cognitive enhancement peptide
How it works
Semax increases expression of BDNF (brain-derived neurotrophic factor) and its receptor TrkB, promoting neurogenesis and synaptic plasticity. It also modulates dopaminergic and serotonergic systems and shows potent neuroprotective effects during ischemia.
What the research explores
In published research, Semax has been studied in connection with the following. These describe findings reported in the literature — not approved uses, claims, or outcomes to expect.
- Significantly upregulates BDNF expression
- Enhances memory formation and recall
- Increases focus and cognitive processing speed
- Neuroprotective against ischemia and oxidative stress
- Anxiolytic effects without sedation
- Approved in Russia for stroke recovery and ADHD
Semax is an approved pharmaceutical in Russia for cognitive enhancement and stroke rehabilitation, backed by decades of research from the Institute of Molecular Genetics of the Russian Academy of Sciences.
Adverse events & gaps
Well-tolerated in clinical use. Possible mild nasal irritation with intranasal administration.
Stay Informed on
Peptide Research
Research summaries, newly documented peptides, and clinical trial updates delivered to your inbox.
No spam. Unsubscribe at any time.